Cas:871127-75-2 5-Oxo-5-(3-phenoxyphenyl)pentanoic acid manufacturer & supplier

Chemical Name:5-Oxo-5-(3-phenoxyphenyl)pentanoic acid

CAS.NO:871127-75-2

Synonyms:5-oxo-5-(3-phenoxyphenyl)valeric acid

Molecular Formula:C₁₇H₁₆O₄

Molecular Weight:284.30700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:492.823ºC at 760 mmHg

Density:1.206g/cm3

Index of Refraction:1.578

PSA:63.60000

Exact Mass:284.10500

LogP:3.91650

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-oxo-5-(3-phenoxyphenyl)valeric acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-oxo-5-(3-phenoxyphenyl)valeric acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-oxo-5-(3-phenoxyphenyl)valeric acid Use and application,5-oxo-5-(3-phenoxyphenyl)valeric acid technical grade,usp/ep/jp grade.

Related News: I look forward to working alongside such an ambitious team who are passionate about using cutting-edge technology to solve the health issues of the future and meet the needs of pharma and biotech companies across the globe.” iron-59(3+),oxygen(2-) manufacturers I look forward to working alongside such an ambitious team who are passionate about using cutting-edge technology to solve the health issues of the future and meet the needs of pharma and biotech companies across the globe.” diethyl 1-[3-[acetyl(methyl)amino]phenyl]-5-phenylpyrazole-3,4-dicarboxylate suppliers Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. 9,10-dioxa-anti-(methyl,hydrogen)(methyl,bromo)bimane vendor & factory The three products for which it received the PLI approvals are betamethasone with a production capacity of 12 MT at an investment of Rs 31.43 crore, dexamethasone of 10 MT with an investment of Rs. 26.19 crore and prednisolone of 15 MT at Rs 39. 29 crore. This takes the total investment to Rs 96.91 core.,Jan Vertommen, Senior Director, Commercial Development, Lonza, said, “Increasing our capabilities by adding mid-scale API manufacturing at our site in Nansha will benefit our customers, and especially the many global emerging biotech companies we partner with.